NACUITY

Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company's powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis. The company is pursuing near-term proof-of-concept data in all three programs... Based in Fort Worth, TX, Nacuity is founded by veterans of Alcon Laboratories experienced in research, development, and commercialization of products to address ophthalmic disease and conditions. The company's core science is based on the extensive research of Dr. Peter Campochiaro of the Wilmer Eye Institute involving oxidative stress in the retina. Nacuity has key backing and technical support from Foundation Fighting Blindness and RD Fund, the world's leading private funders of retinal disease research... We aim to bring powerful,..

Also known as: Nacuity Pharmaceuticals, Nacuity Pharmaceuticals, Inc.

Primary location: Fort Worth United States